Abstract: A disc plow weight mounting bracket device is provided. The device is designed to be used to allow a user to easily and securely attach weight to a disc plow frame, specifically above a disc gang. A base plate and a secondary base plate can be used to attach the device to the frame of a disc plow. Then, the weight can be slid onto the vertical member and secured on the vertical member via the fastener to provide additional weight to the plow, specifically above the disc gang.

Abstract: A purified, isolated DNA sequence encoding human bactericidal/permeability-increasing protein and biologically-active fragments thereof is provided.

Abstract: Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A2 (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.

Abstract: A purified, isolated DNA sequence encoding human bactericidal/permeability-increasing protein and biologically-active fragments thereof is provided.

Abstract: Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A2 (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.

Abstract: Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A2 (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.

Abstract: Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.

Abstract: A purified, isolated DNA sequence encoding human bactericidal/permeability-increasing protein and biologically-active fragments thereof is provided.

Abstract: A purified, isolated DNA sequence encoding human bactericidal/permeability-increasing protein and biologically-active fragments thereof is provided.

Abstract: Disclosed herein are methods for killing Gram-positive bacterial infections in animals comprising exposing the bacteria to Gram-positive bactericidal-effective amounts of Type II phospholipase A2. The Type II phospholipase A2 can be isolated from mammalian species including humans, cows, rabbits, rats, mice, cats, and dogs. Type II phospholipase A2 is effective in treating infections in mammals, including humans, caused by gram-positive bacteria such as Staphylococcus aureus. Also disclosed are pharmaceutical formulations for use in the methods.

Abstract: Therapeutic methods using a purified isolated human bactericidal/permeability-increasing protein and biologically-active fragments thereof is provided.

Abstract: A purified, isolated DNA sequence encoding human bactericidal/permeability-increasing protein and biologically-active fragments thereof is provided.

Abstract: A purified, isolated DNA sequence encoding human bactericidal/permeability-increasing protein and biologically-active fragments thereof is provided.

Abstract: Disclosed herein are methods for killing Gram-positive bacterial infections in animals comprising exposing the bacteria to Gram-positive bactericidal-effective amounts of Type II phospholipase A2. The Type II phospholipase A2 can be isolated from mammalian species including humans, cows, rabbits, rats, mice, cats, and dogs. Type II phospholipase A2 is effective in treating infections in mammals, including humans, caused by gram-positive bacteria such as Staphylococcus aureus. Also disclosed are pharmaceutical formulations for use in the methods.

Abstract: A purified, isolated DNA sequence encoding human bactericidal/permeability-increasing protein and biologically-active fragments thereof is provided.

Abstract: Disclosed herein are methods of inhibiting the endotoxin-mediated release of cytokines in a mammal by administering a 30 kD C-terminal fragment of bactericidal/permeability-increasing protein. The disclosed fragments are useful to treat mammals suffering from infections caused by gram-negative bacteria.

Abstract: Disclosed herein are purified isolated mammals polypeptides having the property of potentiating the bacterial growth inhibitory activity of bactericidal/permeability-increasing protein and pharmaceutical formulations comprising these polypeptides. Also disclosed is a method for obtaining mammalian polypeptides having the property of potentiating the bacterial growth inhibitory activity of bactericidal/permeability-increasing protein potentiating activity, and methods for treating gram-negative bacterial infections in mammals and for neutralizing lipopolysaccharides. Also disclosed is a method for the treatment of diseases caused by endotoxins in mammals.

Abstract: A purified, isolated DNA sequence encoding human bactericidal permeability-increasing protein and biologically-active fragments thereof is provided.